NCT01773018View on ClinicalTrials.gov

Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

December 31, 2015

Study Completion Date

May 31, 2016

Conditions
Tumor
Interventions
DRUG

Volitinib

Volitinib(HMPL-504) is a tablet in the form of 25 mg ,100mgand 200 mg,oral,once daily.

Trial Locations (3)

3084

Austin Health, Melbourne

3168

Southern Health and Monash Institute of Medical Research, Clayton

6009

Sir Charles Gairdner Hospital, Nedlands

All Listed Sponsors
collaborator

Sir Charles Gairdner Hospital

OTHER

collaborator

Austin Hospital, Melbourne Australia

OTHER

collaborator

Monash University

OTHER

lead

Hutchison Medipharma Limited

INDUSTRY

NCT01773018 - Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter